Full Press Release Details
IceCure Medical CEO Issues Letter to Shareholders
CAESAREA, Israel, January 4, 2023 -- IceCure
Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation
technology, the ProSense System that destroys tumors by freezing, today released the following letter to shareholders
from its Chief Executive Officer, Eyal Shamir.
In 2022, we built a strong foundation for the road ahead. IceCure is
creating the new standard in tumor therapy, freezing tumors in their tracks through a minimally invasive outpatient procedure that doesn't
disrupt lives and aims to eliminate recurrence. We've reported solid data in breast and kidney cancer this year with investigator-initiated
studies in several other indications ongoing. Throughout 2022, we've delivered on stated goals by bolstering current customer relationships,
developing new partnerships, and innovating the next generation of our cryoablation technology.
2022 Key Achievements
With many accomplishments achieved this past year, IceCure looks forward
to a bright and exciting future in 2023. Stay tuned! We wish you all a healthy and prosperous new year.
About IceCure Medical Ltd.
IceCure Medical Ltd. (Nasdaq:
ICCM) (TASE: ICCM) develops and markets ProSense , an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors
(benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology
is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system
is marketed and sold worldwide for the indications cleared to-date by the FDA and approved in Europe with the CE Mark.
This press release contains
forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995 and other Federal securities laws and Israeli securities laws. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements
in this press release when it discusses its objectives for 2023, including: anticipating the FDA's response to regulatory requests
for approvals; further studies and cooperation efforts with distributors and healthcare providers to collect clinical data and commercialization;
the continued commercial rollout; the belief that the Company is well funded; regulatory filings and approvals for ProSense and other
products; its belief that raising awareness among patients and clinicians of the benefits of minimally invasive cryoablation will drive
demand for its ProSense procedures; and its exploration of collaborations with strategic players in the industry. Because such statements
deal with future events and are based on IceCure's current expectations, they are subject to various risks and uncertainties and
actual results, performance, or achievements of IceCure could differ materially from those described in or implied by the statements in
this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties,
many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Annual Report
on Form 20-F for the year ended December 31, 2021 filed with the Securities Exchange Commission (the "SEC") on April 1, 2022,
as amended, which is available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for
revisions or changes after the date of this release, except as required by law.
email: ronent@icecure-medical.com